This study will investigate the effect of a single dose of PF-04308515 or prednisone on calculated measures of glucose tolerance and insulin resistance by using a modified oral glucose tolerance test.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)
5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Pfizer Investigational Site
Kalamazoo, Michigan, United States
Fold change in AUC (0-4hr) relative to no treatment baseline for plasma glucose, plasma insulin and plasma C-peptide
Time frame: 4 hours
Pharmacodynamic effects on plasma glucose, plasma insulin, and plasma C-peptide
Time frame: 3 days
Safety: adverse events, vital sign measurements, physical examination
Time frame: 3 days
Pharmacokinetics: sparse PF-04308515 plasma samples will be collected
Time frame: 3 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)